FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W96780237> ?p ?o ?g. }

• W96780237 endingPage "1171" @default.
• W96780237 startingPage "1165" @default.
• W96780237 abstract "Abstract One hundred seventy-four patients with progressive or advanced chronic lymphocytic leukemia (CLL) have received initial therapy with fludarabine as a single agent or fludarabine combined with prednisone. The overall response rate was 78% and the median survival was 63 months. No difference in response rate or survival was noted in the 71 patients receiving fludarabine as a single agent compared with the 103 patients who received prednisone in addition. The median time to progression of responders was 31 months and the overall median survival was 74 months. Patients over the age of 70 years had shorter survivals. Patients with advanced stage disease (Rai III and IV) had a somewhat shorter survival than earlier stage patients. More than half the patients who relapsed after fludarabine therapy responded to salvage treatment, usually with fludarabine-based regimens. Second remissions were more common in patients who had achieved a complete remission on their initial treatment. The CD4 and CD8 T-lymphocyte subpopulations decreased to levels in the range of 150 to 200/μL after the first 3 courses of treatment. Although recovery towards normal levels was slow, the incidence of infections was low in patients in remission (1 episode of infection for every 3.33 patient years at risk) and decreased with time off treatment. There was no association of infections or febrile episodes with the use of corticosteroids or the CD4 count at the end of treatment and a poor correlation with the increase in CD4 counts during remission. Infectious episodes were less common in patients who had a complete response compared with partial responders. Richter’s transformation occurred in 9 patients and Hodgkin’s disease occurred in 4 patients. Five other patients died from other second malignancies. Fludarabine appears to be an effective initial induction therapy with a reasonable safety profile for patients with CLL. © 1998 by The American Society of Hematology." @default.
• W96780237 created "2016-06-24" @default.
• W96780237 creator A5006104041 @default.
• W96780237 creator A5027575595 @default.
• W96780237 creator A5028026524 @default.
• W96780237 creator A5030171128 @default.
• W96780237 creator A5035354255 @default.
• W96780237 creator A5038302480 @default.
• W96780237 creator A5038399226 @default.
• W96780237 creator A5057920623 @default.
• W96780237 creator A5090435894 @default.
• W96780237 date "1998-08-15" @default.
• W96780237 modified "2023-10-12" @default.
• W96780237 title "Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy" @default.
• W96780237 cites W1494274243 @default.
• W96780237 cites W1710792668 @default.
• W96780237 cites W1756818535 @default.
• W96780237 cites W1862276309 @default.
• W96780237 cites W1894269341 @default.
• W96780237 cites W1974095075 @default.
• W96780237 cites W2017648142 @default.
• W96780237 cites W2025334762 @default.
• W96780237 cites W2035858908 @default.
• W96780237 cites W2037668098 @default.
• W96780237 cites W2070193300 @default.
• W96780237 cites W2073937764 @default.
• W96780237 cites W2079317120 @default.
• W96780237 cites W2135806859 @default.
• W96780237 cites W2143087936 @default.
• W96780237 cites W2176099867 @default.
• W96780237 cites W2178644389 @default.
• W96780237 cites W2226417367 @default.
• W96780237 cites W2294516256 @default.
• W96780237 cites W2414892177 @default.
• W96780237 cites W2916663880 @default.
• W96780237 cites W4235838915 @default.
• W96780237 cites W60865865 @default.
• W96780237 cites W61714529 @default.
• W96780237 doi "https://doi.org/10.1182/blood.v92.4.1165" @default.
• W96780237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9694704" @default.
• W96780237 hasPublicationYear "1998" @default.
• W96780237 type Work @default.
• W96780237 sameAs 96780237 @default.
• W96780237 citedByCount "414" @default.
• W96780237 countsByYear W967802372012 @default.
• W96780237 countsByYear W967802372013 @default.
• W96780237 countsByYear W967802372014 @default.
• W96780237 countsByYear W967802372015 @default.
• W96780237 countsByYear W967802372016 @default.
• W96780237 countsByYear W967802372017 @default.
• W96780237 countsByYear W967802372018 @default.
• W96780237 countsByYear W967802372019 @default.
• W96780237 countsByYear W967802372020 @default.
• W96780237 countsByYear W967802372021 @default.
• W96780237 countsByYear W967802372022 @default.
• W96780237 countsByYear W967802372023 @default.
• W96780237 crossrefType "journal-article" @default.
• W96780237 hasAuthorship W96780237A5006104041 @default.
• W96780237 hasAuthorship W96780237A5027575595 @default.
• W96780237 hasAuthorship W96780237A5028026524 @default.
• W96780237 hasAuthorship W96780237A5030171128 @default.
• W96780237 hasAuthorship W96780237A5035354255 @default.
• W96780237 hasAuthorship W96780237A5038302480 @default.
• W96780237 hasAuthorship W96780237A5038399226 @default.
• W96780237 hasAuthorship W96780237A5057920623 @default.
• W96780237 hasAuthorship W96780237A5090435894 @default.
• W96780237 hasConcept C120665830 @default.
• W96780237 hasConcept C121332964 @default.
• W96780237 hasConcept C126322002 @default.
• W96780237 hasConcept C141071460 @default.
• W96780237 hasConcept C2776694085 @default.
• W96780237 hasConcept C2776755627 @default.
• W96780237 hasConcept C2777866208 @default.
• W96780237 hasConcept C2777938653 @default.
• W96780237 hasConcept C2778461978 @default.
• W96780237 hasConcept C2778720950 @default.
• W96780237 hasConcept C2779263901 @default.
• W96780237 hasConcept C61511704 @default.
• W96780237 hasConcept C71924100 @default.
• W96780237 hasConcept C90924648 @default.
• W96780237 hasConceptScore W96780237C120665830 @default.
• W96780237 hasConceptScore W96780237C121332964 @default.
• W96780237 hasConceptScore W96780237C126322002 @default.
• W96780237 hasConceptScore W96780237C141071460 @default.
• W96780237 hasConceptScore W96780237C2776694085 @default.
• W96780237 hasConceptScore W96780237C2776755627 @default.
• W96780237 hasConceptScore W96780237C2777866208 @default.
• W96780237 hasConceptScore W96780237C2777938653 @default.
• W96780237 hasConceptScore W96780237C2778461978 @default.
• W96780237 hasConceptScore W96780237C2778720950 @default.
• W96780237 hasConceptScore W96780237C2779263901 @default.
• W96780237 hasConceptScore W96780237C61511704 @default.
• W96780237 hasConceptScore W96780237C71924100 @default.
• W96780237 hasConceptScore W96780237C90924648 @default.
• W96780237 hasIssue "4" @default.
• W96780237 hasLocation W967802371 @default.
• W96780237 hasOpenAccess W96780237 @default.
• W96780237 hasPrimaryLocation W967802371 @default.

• next